Conestoga Capital Advisors LLC Makes New Investment in Twist Bioscience Corporation $TWST

Conestoga Capital Advisors LLC acquired a new position in shares of Twist Bioscience Corporation (NASDAQ:TWST) during the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund acquired 28,390 shares of the company’s stock, valued at approximately $1,044,000.

A number of other hedge funds and other institutional investors also recently modified their holdings of TWST. GAMMA Investing LLC increased its position in shares of Twist Bioscience by 68.1% during the first quarter. GAMMA Investing LLC now owns 748 shares of the company’s stock worth $29,000 after acquiring an additional 303 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. raised its position in shares of Twist Bioscience by 15.0% in the 2nd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,315 shares of the company’s stock valued at $85,000 after purchasing an additional 302 shares in the last quarter. Bayforest Capital Ltd boosted its stake in shares of Twist Bioscience by 49.3% during the 1st quarter. Bayforest Capital Ltd now owns 4,860 shares of the company’s stock valued at $191,000 after buying an additional 1,604 shares during the last quarter. Hsbc Holdings PLC acquired a new stake in shares of Twist Bioscience during the first quarter worth approximately $228,000. Finally, Xponance Inc. boosted its stake in Twist Bioscience by 22.0% during the 1st quarter. Xponance Inc. now owns 5,953 shares of the company’s stock valued at $234,000 after acquiring an additional 1,072 shares during the last quarter.

Insider Buying and Selling at Twist Bioscience

In related news, CFO Adam Laponis sold 5,875 shares of the stock in a transaction dated Monday, October 6th. The shares were sold at an average price of $32.19, for a total value of $189,116.25. Following the sale, the chief financial officer owned 97,042 shares of the company’s stock, valued at $3,123,781.98. This trade represents a 5.71% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, SVP Paula Green sold 9,724 shares of Twist Bioscience stock in a transaction dated Monday, October 6th. The shares were sold at an average price of $32.19, for a total transaction of $313,015.56. Following the completion of the sale, the senior vice president owned 114,678 shares in the company, valued at approximately $3,691,484.82. This represents a 7.82% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 64,368 shares of company stock valued at $2,036,204. Corporate insiders own 3.01% of the company’s stock.

Wall Street Analysts Forecast Growth

TWST has been the subject of several research analyst reports. Cowen reissued a “buy” rating on shares of Twist Bioscience in a research report on Monday, August 4th. Evercore ISI lowered their price objective on Twist Bioscience from $46.00 to $42.00 and set an “outperform” rating for the company in a report on Tuesday, October 7th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Twist Bioscience in a report on Wednesday, October 8th. Finally, Barclays lowered their price target on Twist Bioscience from $45.00 to $40.00 and set an “overweight” rating for the company in a report on Thursday, October 2nd. Nine research analysts have rated the stock with a Buy rating and two have issued a Sell rating to the company’s stock. According to MarketBeat.com, Twist Bioscience presently has an average rating of “Moderate Buy” and a consensus target price of $48.56.

Twist Bioscience Stock Performance

Shares of TWST stock opened at $28.16 on Monday. The company has a market cap of $1.70 billion, a P/E ratio of -19.42 and a beta of 2.38. The business has a 50 day moving average of $27.98 and a two-hundred day moving average of $32.23. Twist Bioscience Corporation has a 52 week low of $24.07 and a 52 week high of $55.33. The company has a quick ratio of 3.60, a current ratio of 3.90 and a debt-to-equity ratio of 0.03.

Twist Bioscience (NASDAQ:TWST) last announced its quarterly earnings results on Monday, August 4th. The company reported ($0.47) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.54) by $0.07. Twist Bioscience had a negative return on equity of 29.03% and a negative net margin of 23.51%.The business had revenue of $96.06 million for the quarter, compared to the consensus estimate of $95.52 million. Twist Bioscience has set its FY 2025 guidance at EPS. Q4 2025 guidance at EPS. As a group, analysts anticipate that Twist Bioscience Corporation will post -2.12 EPS for the current year.

About Twist Bioscience

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.